Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more…

In this Issue

Six-Month Follow-Up Data Shows Psilocybin Outperforms Escitalopram… or Does It?

Survey Reveals Healthcare Practitioner Attitudes to Psychedelics

MIND Foundation Plots 700-Patient Psilocybin Study

Beckley Psytech-affiliated Study of Low-Dose Psilocybin for Headache Disorder Terminated Due to Recruitment Difficulties

More Headlines

***

Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Already a member? Log In

✓   Regular Bulletins covering key topics and trends in the psychedelics space
✓   Regular articles and deep dives across psychedelic research, policy and business
✓   Interviews with insiders
✓   Monthly interactive database and commentary on psychedelic patents
✓   Quick-take analysis of major developments
✓   A Library of primers and explainers
✓   Access to our full back catalogue

Learn more about Pα+

AbbVie (ABBV) and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders | Psychedelic Invest

AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie’s expertise in psychiatry and Gilgamesh’s

May 13, 2024

China NMPA approves Dizal’s golidocitinib for PTCL treatment

PTCL represents a diverse group of aggressive non-Hodgkin lymphomas, with patients at a high risk of disease relapse. Credit: Nemes Laszlo / Shutterstock. The National

June 20, 2024

New strategy for mRNA nanocarriers using triphenyl phosphonium

Among the vastly different ways of tackling a disease, controlling the genetic expression of cells is undoubtedly one of the most powerful. Over the past

July 23, 2024

Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more… – Psychedelic Alpha

In this Issue

AbbVie (ABBV) and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders | Psychedelic Invest

China NMPA approves Dizal’s golidocitinib for PTCL treatment

New strategy for mRNA nanocarriers using triphenyl phosphonium

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more… – Psychedelic Alpha

In this Issue

AbbVie (ABBV) and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders | Psychedelic Invest

China NMPA approves Dizal’s golidocitinib for PTCL treatment

New strategy for mRNA nanocarriers using triphenyl phosphonium

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe